Biomarkers for immunotherapy: Results from the analysis of an HLA-status double-blind, biologically randomized phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line therapy for advanced colorectal cancer (FXV study).

Shoichi Hazama,Yusuke Nakamura,Hiroaki Tanaka,Ko Tahara,Ryoichi Shimizu,Fumiaki Sugiura,Kiyotaka Okuno,Koichiro Sakata,Kazuhiko Yoshimatsu,Hiroko Takenouchi,Ryouichi Tsunedomi,Yuka Inoue,Shinsuke Kanekiyo,Yoshitaro Shindo,Shigefumi Yoshino,Hirokazu Shinozaki,Hiroyuki Furukawa,Tomonobu Fujita,Yutaka Kawakami,Masaaki Oka

Biomarkers for immunotherapy: Results from the analysis of an HLA-status double-blind, biologically randomized phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line therapy for advanced colorectal cancer (FXV study).

2014

3038 Background: Biomarkers to predict the efficacy of immunotherapy have been awaited. A phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line thera...

Keywords:

Epitope
Pathology
Phases of clinical research
Immunotherapy
Cancer research
Colorectal cancer
Oxaliplatin
Biomarker (medicine)
Human leukocyte antigen
Medicine
Chemotherapy
Oncology
first line therapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations